Following nanoCRISPR treatment, we observed a substantial 52% improvement in BCL-2 gene editing efficiency and an approximately 130-fold upregulation of Bax mRNA expression in tumor cells compared to control groups, leading to comprehensive regulation of the BCL-2/BAX axis and robust tumor apoptosis. The gene discussed is BCL2; the disease is neoplasm.